PIK3CA and cancer: Additionally, examining how PIK3CA mutations may modulate treatment response, particularly to temozolomide, is critical, given the current evidence of these mutations conferring resistance to multiple therapeutic strategies in other cancers [64,82,88,89,90,91,92,99,101,104].